Limb-girdle Muscular Dystrophy

272 Users are discussing this topic

PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

See also: Duchenne Muscular Dystrophy written for patients

The term limb-girdle muscular dystrophy (LGMD) refers to a group of rare, inherited disorders which predominantly affect the muscles around the shoulder girdle and hip girdle, causing progressive muscle weakness.[1] Other muscles, including the heart, may be affected in some types of LGMD. The individual forms of LGMD vary widely in their genetics and clinical features.[2]

There are over 30 subtypes of LGMD.[3] LGMD includes 15 autosomal recessive subtypes and seven autosomal dominant subtypes. Autosomal recessive dystrophy is far more common than autosomal dominant dystrophy.[4] See the table at the bottom for further details of the individual LGMD types.

NEW - log your activity

  • Notes
    Add notes to any clinical page and create a reflective diary
  • Track
    Automatically track and log every page you have viewed
  • Print
    Print and export a summary to use in your appraisal
Click to find out more »

Several different aspects of muscle function seem to be involved.

Currently, LGMDs are classified into two main groups: autosomal dominant (group 1) or recessive (group 2). Within these groups, the subtypes are designated by letters (allocated in chronological order of gene identification).

The terminology of LGMDs may also relate to the protein involved in the pathology - eg, LGMDs 2C-F are termed sarcoglycanopathies. Other proteins involved include dystroglycan, fukutin-related protein, calpain, dysferlin and telethonin.[5]

  • The LGMDs individually are rare, with some forms reported in only a few families.
  • LGMD2A is the most frequent type of LGMD worldwide.[6] 
  • The recessive forms are more common than the autosomal dominant forms.
  • In the UK, LGMDs comprised 6.2% of the population of a specialist muscle clinic, giving a prevalence of 2.27/100,000.[7]

By definition, all LGMDs involve the proximal muscles of the shoulder and pelvic girdles. However, the precise symptoms and signs will vary with the different forms of LGMD. In addition to proximal muscle weakness, there may or may not be:

  • Distal muscle weakness.
  • Muscle hypertrophy.
  • Contractures.
  • Involvement of the heart, respiratory muscles or tongue. (Facial weakness is not usual.)
  • Variation in the clinical expression of the condition, with clinical differences between individuals in one family.
  • Variable age of onset and rates of progression. Also, note that the muscle weakness does not necessarily progress at a linear rate.

Usually there is no intellectual impairment.

See the table below (in 'Appendix') for details of the individual LGMD types and their clinical features.


LGMD is relatively rare: consider more likely diagnoses first. Reaching a diagnosis involves combining information from the clinical presentation and various investigations, mainly serum creatine kinase (CK), muscle biopsy and genetic testing.


  • Ethnic and geographical origin - certain LGMDs have been found in specific regions or countries.
  • Family history.
  • Neonatal history.
  • Childhood development and motor milestones.
  • Sporting ability.


  • Ability to rise from the floor.
  • Is there a finding (or history) of Gower's sign? This is seen in patients with proximal muscle weakness of the lower limb: when rising to stand, they use the hands as support, such that the hands 'climb up the legs'. This sign is common in Duchenne muscular dystrophy.
  • Spinal rigidity or scoliosis.
  • Muscle weakness, hypertrophy or contractures (including calf and tongue hypertrophy).
  • Note:
    • The mode of presentation and the pattern of muscle involvement.
    • Whether there are any additional clinical features.

Interpretation of clinical patterns

The precise clinical pattern and course can help identify the specific LGMD cause. For example:

  • Neonatal hypotonia occurs in LGMD 1B.
  • Contractures are most common in LGMD 1B.
  • LGMD 2A - there is relative preservation of hip abductors and striking involvement of the posterior thigh muscles seen on MRI.
  • LGMD 2A and LGMD 2C-F - scapular winging is characteristic.
  • LGMD 2B - often have normal sporting ability until there is abrupt onset of symptoms.
  • LGMD 1C - may have rippling muscle disease, characterised by signs of increased muscle irritability, such as percussion-induced rapid contraction, percussion-induced muscle mounding and/or electrically silent muscle contractions (rippling muscle).[9]

Specialist centres

  • In the UK, the Newcastle Muscle Centre is the national LGMD diagnostic and advisory service.[10]
  • The Dubowitz Neuromuscular Centre in London provides a diagnostic and advisory service for congenital muscular dystrophies and congenital myopathies.[11]

Key investigations are:

  • Serum CK:
    • This is often raised in LGMD, but can be normal in some types.
    • Exclude non-muscle conditions first.
    • The degree of CK elevation helps distinguish between different types.
  • Muscle imaging with CT or MRI - can show patterns of muscle involvement.[12]
  • Muscle biopsy:
    • This is most useful on muscle which is affected clinically but is not 'end-stage'.
    • Analysed by immunohistochemistry and immunoblotting in an expert laboratory.
    • All LGMDs show dystrophic features with variations in fibre size, greater numbers of central nuclei and endomysial fibrosis.
    • Muscle biopsy immuno-analysis can suggest the diagnosis in many of the genetically defined types of LGMD.
  • DNA analysis:
    • This is the 'gold standard' test, but its feasibility varies for different types of LGMD.
    • It requires a specialist laboratory.
    • For the rarer types of LGMD, this may only be available on a research basis.

In addition:

  • Myoglobinuria can occur in LGMD2I.[1] It has been reported in a patient with sarcoglycanopathy.[13]
  • Cardiac and respiratory investigations are often appropriate, to monitor for complications (see 'Complications and their management', below).

It is possible to reach a precise diagnosis in around 75% of the LGMD patients.

Genetic counselling should be offered. If the specific subtype of LGMD can be identified, prenatal diagnosis or carrier testing for other family members may be possible.

There is no specific therapy for LGMD.[14] 

Nondrug treatment

  • Physiotherapy to prevent contractures, using passive stretching, exercise therapy, ± orthoses.[15]
  • Exercise - the role of exercise in LGMD is controversial, but guidelines for other types of muscular dystrophy suggest gentle exercise within limits of comfort, and avoidance of prolonged immobility.
  • Occupational therapy and aids such as a wheelchair, with careful attention to seating so as to minimise the development of scoliosis.
  • Genetic counselling.
  • Advice on benefits.
  • Support groups (eg, Muscular Dystrophy Campaign).
  • Monitoring for complications (see 'Complications and their Management', below).

Possible drug treatment

  • Corticosteroids have been used in some patients with LGMD 2C-F, giving improvement in some reported cases.[2][16]
  • A study involving two patients with dysferlin-deficient muscular dystrophy reported an improvement in muscle strength after treatment with rituximab.[17]

Complications vary, depending on the specific LGMD and on individual variations in the clinical picture. Cardiac and respiratory surveillance are particularly important in LGMD 1B, LGMD 2C-F and LGMD 2I. Where the type of LGMD carries a high risk of cardiac or respiratory involvement, management should involve cardiac and respiratory physicians. This also applies in cases where the precise diagnosis is unknown.

Respiratory muscle weakness

This is most common in LGMD 2I and the sarcoglycanopathies. It leads to hypoventilation, which is often worse at night. Symptoms include frequent chest infections, morning headaches and daytime sleepiness. Management involves:

  • Monitoring of forced vital capacity (FVC) - sitting and supine - and overnight pulse oximetry, which is helpful.
  • Influenza and pneumococcal vaccines; prompt treatment of infections.
  • Nocturnal home ventilation if required.
  • Other respiratory support if required. See separate Duchenne Muscular Dystrophy article.

Cardiac complications

Dilated cardiomyopathy and/or conduction defects can occur in some forms of LGMD; they are common in LGMD 1B. Monitoring of cardiac function (under a cardiologist) is advised for LGMD 1B, LGMD 2C-F and LGMD 2I; or for where the LGMD type is unknown. Management involves:

  • ECG and echocardiography as initial investigations.
  • Standard management of heart failure.
  • Management of arrhythmias - eg, anticoagulation, pacemaker, implantable defibrillator.
  • If there is severe cardiac impairment with good respiratory function, cardiac transplantation may be appropriate.


  • Rarely, a malignant hyperthermic reaction to general anaesthesia can occur.
  • Caution is needed regarding possible cardiac complications.
  • As in any muscle disease, succinylcholine administration could cause life-threatening hyperkalaemia and should be avoided.

Musculoskeletal complications

  • Contractures (eg, of the Achilles tendon) may require surgical release.
  • Scoliosis - occurs mainly after wheelchair dependence. Careful attention to seating is important.
  • Chronic pain can occur, and pain management should be part of care.[19]

This depends on the type of LGMD and whether there is cardiac or respiratory involvement. In general, all types of LGMD progress with time. However, this is highly variable between the different LGMD types and also between individuals with the same specific type or within a family.[20] Also, the rate of progression is not necessarily linear.[2]

Possible future treatments include:

  • Antisense-mediated exon skipping - this is a promising therapeutic approach for Duchenne muscular dystrophy. It may be applicable to conditions caused by mutations in the dysferlin gene - eg, LGMD 2B and Miyoshi myopathy.[21]
  • Gene therapy is a potential form of treatment.[22]
Types of LGMD and their clinical features[1][7][8]
Type of LGMD (and the protein involved, if known)Usual age of onset (approximate)Notable clinical features (in addition to proximal muscle weakness)
  • So far, this is described only in two families.
  • May have nasal speech.
  • May have cardiac and respiratory involvement.
  • There are no contractures or muscle hypertrophy.
  • May have normal CK.
  • May have distal muscle weakness.
(lamin A/C)
  • May have neonatal hypotonia.
  • There is usually slow progression.
  • Cardiac involvement, including arrhythmias, is common and may be the only manifestation of the condition; may require an implantable defibrillator.
  • May have respiratory involvement.
  • May have distal muscle weakness and contractures.
(caveolin 3)
Childhood - adult
  • Rippling muscle disease (see 'Presentation' section).
  • Cramps and myalgia after exercise are common.
  • There is usually slow progression.
  • Usually there is no cardiac or respiratory involvement.
  • May have muscle hypertrophy and distal muscle weakness.
  • Extraocular muscle involvement has been reported in one case.[23]
LGMD 1D-FAdulthood
  • This is very rare.
  • Proximal weakness with cardiac conduction defects and, later, dilated cardiomyopathy.
  • May have normal CK.
(calpain 3)
Childhood (8-15)
  • There is mainly proximal muscle weakness.
  • There is slow progression.
  • Muscle atrophy is prominent (notable sparing of the hip abductors).
  • Contractures are common.
  • Usually there is no cardiac or respiratory involvement.
  • One case is reported as presenting with foot drop - aged 41.[24]
also known as Miyoshi myopathy
Late teens, early 20s
  • May have distal myopathy (Miyoshi myopathy).
  • Markedly elevated CKs.
  • Usually there is no cardiac or respiratory involvement.
  • Many patients have good muscle strength, leading to good performance at sports or in physically demanding jobs, before onset of symptoms.[25]
  • May have calf muscle pain and swelling.
(sarcoglycan proteins)
  • There is a variable rate of progression.
  • Contractures may develop.
  • Cardiac involvement and respiratory involvement are common.
  • This is rare outside Brazil.
  • There is distal leg weakness.
  • May have cardiac involvement; there is no respiratory involvement.
  • May have normal CK.
(TRIM 32)
Young adult
  • This is rare outside Canada.
  • May have mild facial weakness.
  • May have cardiac involvement; there is no respiratory involvement.
  • May have normal CK.
LGMD type 2I (fukutin-related proteinopathy)Variable
  • This is relatively common in northern Europe. There is variable rate of progression.
  • May develop myalgia, myoglobinuria, contractures, muscle hypertrophy.
  • May have cardiac and respiratory complications - in some cases, the cardiac muscle is more affected than the skeletal muscle;[26] diaphragmatic involvement may cause respiratory insufficiency while still ambulant.
  • So far, this is only reported in Finland.
  • May have cardiac involvement and distal myopathy.
  • Heterozygotes have a distal myopathy.
(protein O-mannosyltransferase 1 (POMT1))
  • Severe learning difficulties and microcephaly.
  • Calf muscle hypertrophy.
  • A few cases have been described in Turkish and English families.
  • There is deterioration of weakness with viral infections.
  • May have cardiac and respiratory involvement.
LGMD 2MAge 10-50
  • There is asymmetric wasting of leg muscle (quadriceps femoris).
Childhood (?)
  • This has been described recently.
  • There is a wide spectrum of symptoms - from a milder form of LGMD to severe muscle weakness and wasting.
  • May have learning difficulties.
  • May have eye problems.

Further reading & references

  1. Guglieri M, Bushby K; How to go about diagnosing and managing the limb-girdle muscular dystrophies. Neurol India. 2008 Jul-Sep;56(3):271-80.
  2. EFNS guideline on diagnosis and management of limb girdle muscular dystrophies; European Federation of Neurological Societies (2007)
  3. Thompson R, Straub V; Limb-girdle muscular dystrophies - international collaborations for translational research. Nat Rev Neurol. 2016 Apr 1. doi: 10.1038/nrneurol.2016.35.
  4. Rosales XQ, Tsao CY; Childhood onset of limb-girdle muscular dystrophy. Pediatr Neurol. 2012 Jan;46(1):13-23. doi: 10.1016/j.pediatrneurol.2011.08.014.
  5. Guglieri M, Straub V, Bushby K, et al; Limb-girdle muscular dystrophies. Curr Opin Neurol. 2008 Oct;21(5):576-84.
  6. Mahmood OA, Jiang XM; Limb-girdle muscular dystrophies: where next after six decades from the first proposal (Review). Mol Med Rep. 2014 May;9(5):1515-32. doi: 10.3892/mmr.2014.2048. Epub 2014 Mar 13.
  7. Norwood FL, Harling C, Chinnery PF, et al; Prevalence of genetic muscle disease in Northern England: in-depth analysis of a Brain. 2009 Nov;132(Pt 11):3175-86. Epub 2009 Sep 18.
  8. Bushby K; Diagnosis and management of the limb girdle muscular dystrophies. Pract Neurol. 2009 Dec;9(6):314-23.
  9. Bruno C, Sotgia F, Gazzerro E, et al; Caveolinopathies. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. 2007 May 14 [updated 2012 Sep 06].
  10. Newcastle Muscle Centre; Insititute of Genetic Medicine, Newcastle University
  11. Dubowitz Neuromuscular Centre; Great Ormond Street Hospital for Children
  12. Wattjes MP, Kley RA, Fischer D; Neuromuscular imaging in inherited muscle diseases. Eur Radiol. 2010 Oct;20(10):2447-60. Epub 2010 Apr 27.
  13. Pena L, Kim K, Charrow J; Episodic myoglobinuria in a primary gamma-sarcoglycanopathy. Neuromuscul Disord. 2010 May;20(5):337-9. Epub 2010 Mar 30.
  14. Pegoraro E, Hoffman EP; Limb-Girdle Muscular Dystrophy Overview. Updated August 2012.
  15. Yeldan I, Gurses HN, Yuksel H; Comparison study of chest physiotherapy home training programmes on respiratory functions in patients with muscular dystrophy. Clin Rehabil. 2008 Aug;22(8):741-8.
  16. Wong-Kisiel LC, Kuntz NL; Two siblings with limb-girdle muscular dystrophy type 2E responsive to Neuromuscul Disord. 2010 Feb;20(2):122-4. Epub 2010 Jan 13.
  17. Lerario A, Cogiamanian F, Marchesi C, et al; Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy. BMC Musculoskelet Disord. 2010 Jul 11;11:157.
  18. Richa FC; Anaesthetic management of a patient with limb-girdle muscular dystrophy for laparoscopic cholecystectomy. Eur J Anaesthesiol. 2011 Jan;28(1):72-3.
  19. Engel JM, Kartin D, Carter GT, et al; Pain in youths with neuromuscular disease. Am J Hosp Palliat Care. 2009 Oct-Nov;26(5):405-12.
  20. Limb-girdle muscular dystrophies; Muscular Dystrophy Campaign
  21. Aartsma-Rus A, Singh KH, Fokkema IF, et al; Therapeutic exon skipping for dysferlinopathies? Eur J Hum Genet. 2010 Aug;18(8):889-94. Epub 2010 Feb 10.
  22. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, et al; Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol. 2009 Sep;66(3):290-7.
  23. Filosto M, Tonin P, Vattemi G, et al; Chronic ophthalmoparesis in limb girdle muscular dystrophy 1C. J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):448-9.
  24. Burke G, Hillier C, Cole J, et al; Calpainopathy presenting as foot drop in a 41 year old. Neuromuscul Disord. 2010 Jun;20(6):407-10.
  25. Klinge L, Aboumousa A, Eagle M, et al; New aspects on patients affected by dysferlin deficient muscular dystrophy. J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):946-53. Epub 2009 Jun 14.
  26. Margeta M, Connolly AM, Winder TL, et al; Cardiac pathology exceeds skeletal muscle pathology in two cases of limb-girdle muscular dystrophy type 2I. Muscle Nerve. 2009 Nov;40(5):883-9.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Olivia Scott
Current Version:
Peer Reviewer:
Dr John Cox
Document ID:
1498 (v24)
Last Checked:
Next Review:

Did you find this health information useful?

Yes No

Thank you for your feedback!

Subcribe to the Patient newsletter for healthcare and news updates.

We would love to hear your feedback!

Patient Access app - find out more Patient facebook page - Like our page